|本期目录/Table of Contents|

[1]陈丽华 综述,莫纯坚 审校.抗VEGF药物治疗糖尿病黄斑水肿的临床应用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):414-417.[doi:10.3969/j.issn.1672-271X.2015.04.025]
点击复制

抗VEGF药物治疗糖尿病黄斑水肿的临床应用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年04期
页码:
414-417
栏目:
综述
出版日期:
2015-07-20

文章信息/Info

Title:
-
作者:
陈丽华 综述; 莫纯坚 审校
443003 湖北宜昌，宜昌市中心人民医院眼视光学专科
Author(s):
-
关键词:
血管内皮生长因子; 糖尿病黄斑水肿; 雷珠单抗; 哌加他尼钠; 贝伐单抗; 阿柏西普
Keywords:
-
分类号:
R774.5
DOI:
10.3969/j.issn.1672-271X.2015.04.025
文献标志码:
A
摘要:
糖尿病黄斑水肿(diabetic macular edema，DME)是发达国家致盲性眼病的重要原因，血管内皮生长因子(vascular endothelial growth factor，VEGF)在DME的发生发展中发挥重要作用，成为DME的重要治疗靶点。近年来的研究结果显示抗VEGF药物的治疗效果优于传统激光或糖皮质激素。本文综述抗VEGF药物最新的研究进展。
Abstract:
-

参考文献/References:

［1］王爱民，徐向进，熊晓琴，等.2 型糖尿病患者长期家庭血糖监测的随访分析［J］.东南国防医药，2014，16(1):40-42.
［2］Jain A，Collen J，Kaines A，et al． Short-duration focal pattern grid macular photocoagulation for diabetic macular edema:four-month outcomes［J］.Retina，2010，30(10):1622-1626.
［3］Soheilian M，Garfami KH，Ramezani A，et al.Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema［J］.Retina，2012，32(2):314-321.
［4］Bringmann A，Reichenbach A，Wiedemann P.Pathomechanisms of cystoid macular edema［J］.Ophthalmic Res，2004，36(5):241-249.
［5］Lee SN，Chhablani J，Chan CK，et al.Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema［J］.Am J Ophthalmol，2013，155(5):905-912.
［6］Zhang C，Wang H，Nie J，et al.Protective factors in diabetic retinopathy:focus on blood-retinal barrier［J］.Discov Med，2014，18(98):105-112.
［7］Miller JW，Le Couter J，Strauss EC，et al.Vascular endothelial growth factor a in intraocular vascular disease［J］.Ophthalmology，2013，120(1):106-114.
［8］Papadopoulos N，Martin J，Ruan Q，et al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap，ranibizumab and bevacizumab［J］.Angiogenesis，2012，15(2):171-185.
［9］Stewart MW.Anti-vascular endothelial growth factor drug treatment of diabetic macular edema:the evolution continues［J］.Curr Diabetes Rev，2012，8(4):237-246.
［10］Funatsu H，Yamashita H，Noma H，et al.Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema［J］.Am J Ophthalmol，2002，133(1):70-77.
［11］Funatsu H，Yamashita H，Sakata K，et al.Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema［J］.Ophthalmology，2005，112(5):806-816.
［12］Cheung N，Mitchell P，Wong TY.Diabetic retinopathy［J］.Lancet，2010，376(9735):124-136.
［13］Yu L，Liang XH，Ferrara N.Comparing protein VEGF inhibitors:in vitro biological studies［J］.Biochem Biophys Res Commun，2011，408(2):276-281.
［14］Chen G，Li W，Tzekov R，et al.Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema:a meta-analysis of randomized controlled trials［J］.PLoS One，2014，9(12):e115797.
［15］Liegl R，Langer J，Seidensticker F，et al.Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema［J］.PLoS One，2014，9(12):e113981.
［16］Yanagida Y，Ueta T.Systemic safety of ranibizumab for diabetic macular edema:meta-analysis of randomized trials［J］.Retina，2014，34(4):629-635.
［17］Ishibashi T，Yuzawa M，Yoshimura N，et al.Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema［J］.Nihon Ganka Gakkai Zasshi，2014，118(9):773-782.
［18］Sivaprasad S，Browning RC，Starita C.An open-label，one-year，noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema［J］.Clin Ophthalmol，2014，21(8):1565-1571.
［19］Liu XD，Zhou XD，Wang Z，et al.Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema:a systemic review and Meta-analysis［J］.Int J Ophthalmol，2014，7(6):1048-1055.
［20］Liu X，Zhou X，Wang Z，et al.Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema:a meta-analysis of randomized controlled trials［J］.Chin Med J (Engl)，2014，127(19):3471-3476.
［21］Palejwala NV，Lauer AK.Aflibercept:an update on recent milestones achieved［J］.Drugs Today (Barc)，2014，50(12):779-790.
［22］Al-Halafi AM.Vascular endothelial growth factor trap-eye and trap technology:Aflibercept from bench to bedside［J］.Oman J Ophthalmol，2014，7(3):112-115.
［23］Korobelnik JF，Do DV，Schmidt-Erfurth U，et al.Intravitreal af-libercept for diabetic macular edema［J］.Ophthalmology，2014，121(11):2247-2254.

相似文献/References:

[1]林夏雯,李爱梅,施 鸣,等.部分胃癌PET-CT显像与HIF-1α等指标的相关分析[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):407.
　LIN Xia-wen,LI Ai-mei,SHI Ming,et al.Analysis of relationship among HIF-1α,COX-2,VEGF and SUVmax in gastric cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(04):407.
[2]周建平,周伟平.大肝癌TACE后肿瘤组织VEGF、αv整合素表达及MVD变化[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):206.
　ZHOU Jian-ping,ZHOU Wei-ping.Expression of VEGF, integrin-αV and MVD in viable residual tumor tissues from large hepatocellular carcinoma after TACE[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(04):206.
[3]胡翰青,刘 蔚,马行健,等.P53蛋白、VEGF和CD34在涎腺腺样囊性癌中的表达及意义[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):592.[doi:10.3969/j.issn.1672-271X.2013.06.012]
　HU Han-qing,LIU Wei,MA Xing-jian,et al.Expression and clinical significance of P53 protein,VEGF and CD34 in human salivar adenoid cystic carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):592.[doi:10.3969/j.issn.1672-271X.2013.06.012]
[4]任建枝,蔡嘉力,韩冬梅,等.胚胎培养液中血管内皮生长因子的水平及其与IVF-ET结局的关系[J].医学研究与战创伤救治(原医学研究生学报),2016,18(05):472.[doi:10.3969/j.issn.1672-271X.2016.05.007]
　REN Jian-zhi,CAI Jia-li,HAN Dong-mei,et al.Vascularendothelial growth factor level in embryo culture medium and its impact on clinical outcome of IVF-ET[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(04):472.[doi:10.3969/j.issn.1672-271X.2016.05.007]
[5]梁紫君,安红伟.ICAM-1、VEGF及ox-LDL与缺血性脑血管病患者颅内外动脉重度狭窄或闭塞的相关性[J].医学研究与战创伤救治(原医学研究生学报),2022,24(5):454.[doi:10.3969/j.issn.1672-271X.2022.05.002]
　LIANG Zi-jun,AN Hong-wei.Relationship between ICAM-1, VEGF, ox-LDL and severe stenosis or occlusion of intracranial and extracranial arteries in patients with ischemic cerebrovascular disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):454.[doi:10.3969/j.issn.1672-271X.2022.05.002]

备注/Memo

备注/Memo:
国家自然科学基金(81470387)
更新日期/Last Update: 2015-07-20